Could Carbon Dioxide Replace Antibiotics in Surgery?
A prize-winning paper suggests that filling a surgical wound with carbon dioxide gas could reduce infection and improve healing
Oxford, UK, 04 February 2009 – The journal Medical Hypotheses, an Elsevier publication, has announced the winner of the 2008 David Horrobin Prize for medical theory. Written by Mikael Persson and Jan van der Linden from the Karolinska Institute in Sweden, the article “Intraoperative CO2 insufflation can decrease the risk of surgical site infection” was judged to best embody the spirit of the journal.
The paper explains that wound infection is a serious surgical complication leading to longer stays in hospital and greater risk of death. Problems include bacterial contamination of the wound, drying of body tissues and heat loss.
The authors suggest that a wound could continuously be flooded with carbon dioxide gas (CO2) during surgery. Carbon dioxide could prevent airborne bacteria from reaching the wound and would also suffocate germs. CO2 is already used for this purpose in the food packaging business. Humidified CO2 would also keep the wound warm and moist, which should reduce tissue damage and speed-up healing.
The authors have already tested their idea in the laboratory, and the next step should be a proper clinical trial in humans.
This year’s prize judge was Sir David Weatherall, Emeritus Regius Professor of Medicine at the University of Oxford. Sir David commented "I chose this because the hypothesis revolves around a very unusual approach to an extremely common and important clinical problem and the authors seem to have gone someway to defining the route to which it could be tested by appropriate clinical trial."
The £1,000 prize, launched in 2004, is awarded annually and named in honour of Dr. David Horrobin, the renowned researcher, biotechnology expert and founder of Medical Hypotheses, who died in 2003.
# # #
Notes to Editors:
The full article reference is: M Persson, J van der Linden. Intraoperative CO2 insufflation can decrease the risk of surgical site infection. Medical Hypotheses. 2008; 71: 8-13
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Tel: +44 1865 843824